You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,466,159


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,466,159
Title:Methods for treating HCV
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Inventor(s): Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Gurnee, IL), Cohen; Daniel E. (Wilmette, IL), Podsadecki; Thomas J. (Chicago, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:13/603,022
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,466,159
Patent Claims: 1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 12 weeks, and wherein said at least two DAAs comprise: Compound 1 having formula of ##STR00012## or a pharmaceutically acceptable salt thereof, and Compound 4 having formula of ##STR00013## or a pharmaceutically acceptable salt thereof, wherein Compound 1 or the salt thereof is co-administered with ritonavir.

2. The method of claim 1, wherein said patient is a treatment-naive patient.

3. The method of claim 1, wherein said at least two DAAs further comprise compound 2 having formula of ##STR00014## or a pharmaceutically acceptable salt thereof.

4. The method of claim 2, wherein said at least two DAAs further comprise compound 2 having formula of ##STR00015## or a pharmaceutically acceptable salt thereof.

5. The method of claim 1, wherein said patient is infected with HCV genotype 1a.

6. The method of claim 2, wherein said patient is infected with HCV genotype 1a.

7. The method of claim 3, wherein said patient is infected with HCV genotype 1a.

8. The method of claim 4, wherein said patient is infected with HCV genotype 1a.

9. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, wherein said at least two DAAs comprise PSI-7977 and TMC-435, and wherein said treatment lasts for 12 weeks.

10. The method of claim 9, wherein said patient is a treatment-naive patient.

11. The method of claim 9, wherein said patient is infected with HCV genotype 1a.

12. The method of claim 10, wherein said patient is infected with HCV genotype 1a.

13. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, wherein said at least two DAAs comprise PSI-7977 and GS-5885, and wherein said treatment lasts for 12 weeks.

14. The method of claim 13, wherein said patient is a treatment-naive patient.

15. The method of claim 13, wherein said patient is infected with HCV genotype 1a.

16. The method of claim 14, wherein said patient is infected with HCV genotype 1a.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.